Entering text into the input field will update the search result below

FDA OKs expanded use of Vertex's CF med Kalydeco; shares ahead 1% after hours

  • The FDA has approved the use of Vertex Pharmaceuticals' (NASDAQ:VRTX) Kalydeco (ivacaftor) for the treatment of cystic fibrosis patients with 33 genetic mutations, up from 10 mutations.
  • The agency based its approval, in part, on laboratory test results. It used these data with results from earlier clinical trials as the basis for its decision, providing a pathway for adding additional CF-related mutations.
  • Shares are up 1% after hours on increased volume.

Recommended For You

More Trending News

About VRTX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
VRTX--
Vertex Pharmaceuticals Incorporated